Whether to Retest the Lipids of HIV-Infected Patients: How Much Does Fasting Bias Matter?

References

• Alonso-Villaverde C., Coll B., Gomez F., Parra S., Camps J., Joven J., Masana L. The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS (2005) 19(3):341–342Google Scholar
• Arvieux C., Tribut O. Amprenavir or fosamprenavir plus ritonavir in HIV infection: Pharmacology, efficacy and tolerability profile. Drugs (2005) 65(5):633–659Crossref, Google Scholar
• Baldini F., Di Giambenedetto S., Cingolani A., Murri R., Ammassari A., De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: A pilot study. AIDS (2000) 14(11):1660–1662Crossref, Google Scholar
• Cahn P. E., Gatell J. M., Squires K., Percival L. D., Piliero P. J., Sanne I. A., Shelton S., et al. Atazanavir—A once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: Results from two randomized clinical trials. J. Internat. Assoc. Physicians AIDS Care (2004) 3(3):92–98Crossref, Google Scholar
• Calza L., Manfredi R., Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS (2003) 17(6):851–859Crossref, Google Scholar
• Calza L., Manfredi R., Colangeli V., Tampellini L., Sebastiani T., Pocaterra D., Chiodo F. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS (2005) 19(10):1051–1058Crossref, Google Scholar
• Cantor S. B. Clinical applications in the decision analysis literature. Decision Anal. (2004) 1(1):23–25(Comment on Keefer et al. 2004)Link, Google Scholar
• Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D. J., Cooper D. A. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12(7):51–58Crossref, Google Scholar
• Chang E. S., Tetreault D. D., Liu Y. T., Beall G. N. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients. J. Amer. Dietetic Assoc. (2001) 101(6):687–689Crossref, Google Scholar
• Crane H. M., Van Rompaey S. E., Kitahata M. M. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS (2006) 20(7):1019–1026Crossref, Google Scholar
• Doser N., Kubli S., Telenti A., Marzolini C., Chave J. P., Feihl F., Buclin T., et al. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS (2002) 16(14):1982–1983Crossref, Google Scholar
• Dube M. P., Qian D., Edmondson-Melanon H., Sattler F. R., Goodwin D., Martinez C., Williams V., Johnson D., Buchanan T. A. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clinical Infectious Diseases (2002) 35(4):475–481Crossref, Google Scholar
• Dube M. P., Stein J. H., Aberg J. A., Fichtenbaum C. J., Gerber J. G., Tashima K. T., Henry W. K., Currier J. S., Sprecher D., Glesby M. J.Adult AIDS Clinical Trials Group Cardiovascular Subcommitte Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Diseases (2003) 37(5):613–627Crossref, Google Scholar
• DuMouchel W. H., Harris J. E. Bayes methods for combining the results of cancer studies in humans and other species. J. Amer. Statist. Assoc. (1983) 78(382):293–308Crossref, Google Scholar
• Efron B., Morris C. Stein's paradox in statistics. Scientific Amer. (1977) 23(6):119–127Crossref, Google Scholar
• Fisac C., Virgili N., Ferrer E., Barbera M. J., Fumero E., Vilarasau C., Podzamczer D. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J. Clinical Endocrinology Metabolism (2003) 88(11):5186–5192Crossref, Google Scholar
• Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry (1972) 18(6):499–502Google Scholar
• Friis-Moller N., Sabin C. A., Weber R., d'Arminio Monforte W. M., El-Sadr A., Reiss P., Thibaut R., et al. Combination antiretroviral therapy and the risk of myocardial infarction. New England J. Medicine (2000) 349(21):1993–2003Google Scholar
• Gelman A., Carlin J., Stern H., Rubin D.Bayesian Data Analysis (2004) 2nd ed.(Chapman & Hall/CRC, Boca Raton, FL) Google Scholar
• Grover S. A., Coupal L., Gilmore N., Mukherjee J. Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. Amer. J. Cardiology (2005) 95(5):586–591Crossref, Google Scholar
• Grundy S. M., Cleeman J. I., Merz C. N., Brewer H. B., Clark L. T., Hunninghake D. B., Pasternak R. C., Smith S. C., Stone N. J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110(2):227–239Crossref, Google Scholar
• Hogg R. S., Heath K. V., Yip B., Crib K. J., O'Shaughnessy M. V., Schechter M. T., Montaner J. S. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J. Amer. Medical Assoc. (1998) 279(6):450–454Crossref, Google Scholar
• Keeney R. L., Vernik D. A. Analysis of the biological clock decision. Decision Anal. (2007) 4(3):114–135Link, Google Scholar
• Kitahata M. M., Reed S. D., Dillingham P. W., Van Rompaey S. E., Young A. A., Harrington R. D., Holmes K. K. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Internat. J. STD AIDS (2004) 15(12):803–810Crossref, Google Scholar
• Kitahata M. M., Dillingham P. W., Chaiyakunapruk N., Buskin S. E., Jones J. L., Harrington R. D., Hooton T. M., Holmes K. K. Electronic human immunodeficiency virus (HIV) clinical reminder system improves adherence to practice guidelines among the University of Washington HIV Study Cohort. Clinical Infectious Diseases (2003) 36(6):803–811Crossref, Google Scholar
• Mallon P. W., Miller J., Cooper D. A., Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (2003) 17(7):971–979Crossref, Google Scholar
• Manfredi R., Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: Frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J. Infection (2001) 42(3):181–188Crossref, Google Scholar
• Miller J., Brown D., Amin J., Kent-Hughes J., Law M., Kaldor J., Cooper D. A., Carr A. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS (2002) 16(6):2195–2200Crossref, Google Scholar
• Mora S., Rifai N., Buring J., Ridker P. M. Fasting compared with nonfasting lipids and apolipoproteins for predicitng incident cardiovascular events. Circulation (2008) 118(10):993–1001Crossref, Google Scholar
• Moyle G. J., Lloyd M., Reynolds B., Baldwin C., Mandalia S., Gazzard B. G. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS (2001) 15(12):1503–1508Crossref, Google Scholar
• Murphy E. L., Collier A. C., Kalish L. A., Assmann S. F., Para M. F., Flanigan T. P., Kumar P. N., Mintz L., Wallach F. R., Nemo G. J.Viral Activation Transfusion Study Investigators Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Internal Medicine (2001a) 135(1):17–26Crossref, Google Scholar
• Murphy R. L., Sanne I., Cahn P., Phanuphak P., Percival L., Kelleher T., Giordano M. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS (2001b) 17(18):2603–2614Crossref, Google Scholar
• National Heart, Lung, and Blood Institute Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. (1998) . NIH Publication 98-4083. Appendix 5. National Heart, Lung, and Blood Institute in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MDGoogle Scholar
• Palacios R., Santos J., Gonzalez M., Ruiz J., Valdivielso P., Marquez M., Gonzalez-Santos P. Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J. Acquired Immune Deficiency Syndromes (2002a) 30(5):536–537Crossref, Google Scholar
• Palacios R., Santos J., Gonzalez M., Ruiz J., Valdivielso P., Marquez M., Gonzalez-Santos P. Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J. Acquired Immune Deficiency Syndromes (2002b) 31(2):251–253Crossref, Google Scholar
• Palella F. J., Delaney K. M., Moorman A. C., Loveless M. O., Fuhrer J., Satten G. A., Aschman D. J., Holmberg S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England J. Medicine (1998) 338(13):853–860Crossref, Google Scholar
• Pauker S. G., Wong J. B. The influence of influence diagrams in medicine. Decision Anal. (2005) 2(4):238–244Link, Google Scholar
• Periard D., Telenti A., Sudre P., Cheseaux J. J., Halfon P., Reymond M. J., Marcovina S. M., et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation (1999) 100(7):700–705Crossref, Google Scholar
• Rhew D. C., Bernal M., Aguilar D., Iloeje U., Goetz M. B. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: A systematic review. Clinical Infectious Diseases (2003) 37(7):959–972Crossref, Google Scholar
• Tsiodras S., Mantzoros C., Hammer S., Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Archives Internal Medicine (2000) 160(13):2050–2056Crossref, Google Scholar
• van der Valk M., Kastelein J. J., Murphy R. L., van Leth F., Katlama C., Horban A., Glesby M., et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 15(18):2407–2414Crossref, Google Scholar
• Visnegarwala F., Maldonado M., Sajja P., Minihan J. L., Rodriguez-Barradas M. C., Ong O., Lahart C. J., Hasan M. Q., Balasubramanyam A., White A. C. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J. Infection (2004) 49(4):283–290Crossref, Google Scholar